Interaction of maternal choline levels and prenatal Marijuana's effects on the offspring Camille Hoffman, Sharon K. Hunter, Angelo D'Alessandro, KathleenNoonan et al. Psychological Medicine, 2019 Doi : https://doi.org/10.1017/S003329171900179X Published online by Cambridge University Press: 31 July 2019 Abstract Background : This study investigated whether higher maternal choline levels mitigate effects of marijuana on fetal brain development. Choline transported into the amniotic fluid from the mother activates α7-nicotinic acetylcholine receptors on fetal cerebro-cortical inhibitory neurons, whose development is impeded by cannabis blockade of their cannabinoid-1(CB1) receptors. Methods : Marijuana use was assessed during pregnancy from women who later brought their newborns for study. Mothers were informed about [...]
Lire la suiteCannabis and the developing brain : Insights from behavior Viviana Trezza, Vincenzo Cuomo, Louk J.M.J. Vanderschuren European Journal of Pharmacology, 2008, 585, 441-452. Doi : 10.1016/j.ejphar.2008.01.058 A B S T R A C T The isolation and identification, in 1964, of delta-9-tetrahydrocannabinol (THC), the primary psycho-active compound in cannabis, opened the door to a whole new field of medical research. The exploration of the therapeutic potential of THC and other natural and synthetic cannabinoid compounds was paralleled by the discovery of the endocannabinoid system, comprising cannabinoid receptors and their endogenous ligands, which offered exciting new insights into brain function. Besides its well-known involvement in specific [...]
Lire la suiteDevelopmental consequences of perinatal cannabis exposure : behavioral and neuroendocrine effects in adult rodents Patrizia Campolongo, Viviana Trezza, Patrizia Ratano, Maura Palmery & Vincenzo Cuomo Psychopharmacology, 2011, 214, 5–15 Doi : 10.1007/s00213-010-1892-x Abstract Rationale : Cannabis is the most commonly used illicit drug among pregnant women. Since the endocannabinoid system plays a crucial role in brain development, maternal exposure to cannabis derivatives might result in longlasting neurobehavioral abnormalities in the exposed offspring. It is difficult to detect these effects, and their underlying neurobiological mechanisms, in clinical cohorts, because of their intrinsic methodological and interpretative issues. Objectives : The present paper reviews relevant rodent studies examining the [...]
Lire la suiteMalades de Parkinson à Marseille, ils vont tester le cannabis thérapeutique La Provence, 24/1/2020 https://www.laprovence.com/article/societe/5858706/avant-premiere-malades-de-parkinson-a-marseille-ils-vont-tester-le-cannabis-therapeutique.html transmis par principesactifs.fr La prise de cannabis peut-elle soulager certains symptômes moteurs et non-moteurs de la maladie de Parkinson ? "Nous avons de bonnes raisons de le penser mais nous avons besoin de données robustes pour le démontrer", sourit le Pr Olivier Blin, chef du service de pharmacologie clinique de la Timone, à Marseille. Grâce au soutien du centre d’excellence Dhune et de l’association France-Parkinson, son équipe, avec le service de neurologie et de pathologie du mouvement, le CNRS et l’Institut de neurosciences du CHU s’apprêtent à tester la prise de [...]
Lire la suiteA novel phytocannabinoid isolated from Cannabis sativa L. with an in vivo cannabimimetic activity higher than Δ9-tetrahydrocannabinol : Δ9-Tetrahydrocannabiphorol Cinzia Citti, Pasquale Linciano, Fabiana Russo, Livio Luongo, Monica Iannotta, Sabatino Maione, Aldo Laganà, Anna Laura Capriotti, Flavio Forni, Maria Angela Vandelli, Giuseppe Gigli & Giuseppe Cannazza Scientific Reports, 2019, 9, 20335 doi : 10.1038/s41598-019-56785-1 2 (-)-Trans-Δ9-tetrahydrocannabinol (Δ9-THC) is the main compound responsible for the intoxicant activity of Cannabis sativa L. The length of the side alkyl chain influences the biological activity of this cannabinoid. In particular, synthetic analogues of Δ9-THC with a longer side chain have shown cannabimimetic properties far higher than Δ9-THC itself. [...]
Lire la suiteBibliographie Cannabinoïdes et Opiacés Dr Christian Sueur, GRECC, janvier 2020.
Lire la suiteThe health and social effects of nonmedical cannabis use World Health Organization, 2016. CONTENTS Foreward. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . v Acknowledgements .. . . . . . . . . . . . . . . . . . . [...]
Lire la suiteAntidepressant-like effects of β-caryophyllene on restraint plus stress-induced depression Eun-Sang Hwang, Hyun-Bum Kim, Seok Lee, Min-Jeong Kim, Kwan-Joong Kim, Gaeul Han, Se-Young Han, Eun-A Lee, Jeong-Hee Yoon, Dae-Ok Kim, Sungho Maeng, Ji-Ho Park Behavioural Brain Research, 2020, 380, 112439 doi : 10.1016/j.bbr.2019.112439 A B S T R A C T Chronic stress is depressogenic by altering neurotrophic and neuroinflammatory environments of the organism. The endocannabinoid system controls cognitive and emotional responses related with stress through the interaction with endocannabinoid receptors. β-Caryophyllene (BCP) is a CB2 agonist that exhibited anti-inflammatory, analgesic effects but minimal psychoactive effects. To test if BCP exhibits antidepressant-like action, animals were chronically restrained with additional [...]
Lire la suiteCannabinoid Regulation of Fear and Anxiety : an Update Eleni P. Papagianni & Carl W. Stevenson Current Psychiatry Reports, 2019, 21, 38 doi : 10.1007/s11920-019-1026-z Abstract Purpose of Review : Anxiety- and trauma-related disorders are prevalent and debilitating mental illnesses associated with a significant socioeconomic burden. Current treatment approaches often have inadequate therapeutic responses, leading to symptom relapse. Here we review recent preclinical and clinical findings on the potential of cannabinoids as novel therapeutics for regulating fear and anxiety. Recent Findings : Evidence from preclinical studies has shown that the non-psychotropic phyto-cannabinoid cannabidiol and the endocannabinoid anandamide have acute anxiolytic effects and also regulate learned fear [...]
Lire la suiteThe cannabinoids : An overview. Therapeutic implications in vomiting and nausea after cancer chemotherapy, in appetite promotion, in multiple sclerosis and in neuroprotection R. Mechoulam PhD, L Hanus PhD Pain Research Management, 2001, 6, (2), 67-73. Doi : 10.1155/2001/183057 The present paper describes the historical use of cannabis, starting with its use in Assyria and China. Recent advances in the understanding of the molecular basis of cannabis action are explained, including the identification of the cannabinoid receptors CB1 and CB2, as well as the isolation of endogenous cannabinoids from the brain and periphery. The use of delta9-tetrahydrocannabinol as an antivomiting and antinausea drug for cancer [...]
Lire la suite